Abstract
Effects Of Emblica Officinalis Commercial Formulation In Type 2 Diabetic Patients
The levels of blood glucose and malondialdehyde in type 2 diabetic patients have been studied after the administration of amalakic capsules containing 250 mg fruit powder of Emblica officinalis twice a day for 60 d. It was observed that the drug treatment decreases blood glucose levels from 203±82 mg/dl (initial) to 189±255.2 mg/dl (after 60 d of treatment). However, the decrease was statistically insignificant (p>0.05). On the other hand, administration of amalaki for the same period of time resulted in a significant decrease in malondialdehyde levels from 7.55±2.3 nM (initial) to 5.36±0.8 nM (after 60 d of treatment). The decrease in the levels of the malondialdehyde was statistically significant (p<0.05). In the present study, no direct relationship was observed between blood glucose levels and malondialdehyde levels (lipid peroxide levels) of type 2 diabetic patients.
